Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank Disease ID
1 Adipocytokine signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
2 African trypanosomiasis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
3 AGE-RAGE signaling pathway in diabetic complications 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
4 Alcoholic liver disease 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
5 Allograft rejection 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
6 Alzheimer disease 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
7 Alzheimer disease 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
8 Alzheimer disease 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
9 Amoebiasis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
10 Amphetamine addiction 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
11 Amphetamine addiction 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
12 Amyotrophic lateral sclerosis 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
13 Amyotrophic lateral sclerosis 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
14 Amyotrophic lateral sclerosis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
15 Antifolate resistance 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
16 Antigen processing and presentation 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
17 Apoptosis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
18 Asthma 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
19 Axon guidance 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
20 Axon guidance 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
21 B cell receptor signaling pathway 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
22 B cell receptor signaling pathway 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
23 C-type lectin receptor signaling pathway 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
24 C-type lectin receptor signaling pathway 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
25 C-type lectin receptor signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
26 Calcium signaling pathway 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
27 Calcium signaling pathway 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
28 Cellular senescence 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
29 Cellular senescence 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
30 cGMP-PKG signaling pathway 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
31 cGMP-PKG signaling pathway 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
32 Chagas disease 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
33 Coronavirus disease - COVID-19 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
34 Cytokine-cytokine receptor interaction 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
35 Dilated cardiomyopathy 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
36 Dopaminergic synapse 💬
 [3] PPP3CA, PPP3CB, PPP3CC 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
37 Dopaminergic synapse 💬
 [3] PPP3CA, PPP3CB, PPP3CC 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
38 Epstein-Barr virus infection 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
39 Fc epsilon RI signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
40 Fluid shear stress and atherosclerosis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
41 Glucagon signaling pathway 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
42 Glucagon signaling pathway 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
43 Glutamatergic synapse 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
44 Glutamatergic synapse 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
45 Graft-versus-host disease 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
46 Hematopoietic cell lineage 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
47 Hepatitis B 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
48 Hepatitis C 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
49 Herpes simplex virus 1 infection 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
50 Human cytomegalovirus infection 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
51 Human cytomegalovirus infection 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
52 Human cytomegalovirus infection 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
53 Human immunodeficiency virus 1 infection 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
54 Human immunodeficiency virus 1 infection 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
55 Human immunodeficiency virus 1 infection 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
56 Human papillomavirus infection 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
57 Human T-cell leukemia virus 1 infection 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
58 Human T-cell leukemia virus 1 infection 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
59 Human T-cell leukemia virus 1 infection 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
60 Hypertrophic cardiomyopathy 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
61 IL-17 signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
62 Inflammatory bowel disease 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
63 Influenza A 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
64 Insulin resistance 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
65 Kaposi sarcoma-associated herpesvirus infection 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
66 Kaposi sarcoma-associated herpesvirus infection 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
67 Legionellosis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
68 Leishmaniasis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
69 Lipid and atherosclerosis 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
70 Lipid and atherosclerosis 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
71 Lipid and atherosclerosis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
72 Long-term potentiation 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
73 Long-term potentiation 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
74 Malaria 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
75 MAPK signaling pathway 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
76 MAPK signaling pathway 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
77 MAPK signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
78 mTOR signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
79 Natural killer cell mediated cytotoxicity 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
80 Natural killer cell mediated cytotoxicity 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
81 Natural killer cell mediated cytotoxicity 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
82 Necroptosis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
83 NF-kappa B signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
84 NOD-like receptor signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
85 Non-alcoholic fatty liver disease 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
86 Oocyte meiosis 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
87 Oocyte meiosis 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
88 Osteoclast differentiation 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
89 Osteoclast differentiation 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
90 Osteoclast differentiation 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
91 Oxytocin signaling pathway 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
92 Oxytocin signaling pathway 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
93 Pathogenic Escherichia coli infection 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
94 Pathways of neurodegeneration - multiple diseases 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
95 Pathways of neurodegeneration - multiple diseases 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
96 Pathways of neurodegeneration - multiple diseases 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
97 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
98 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
99 Pertussis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
100 Prion disease 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
101 Prion disease 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
102 Prion disease 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
103 Proteoglycans in cancer 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
104 Renin secretion 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
105 Renin secretion 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
106 Rheumatoid arthritis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
107 RIG-I-like receptor signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
108 Salmonella infection 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
109 Shigellosis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
110 Sphingolipid signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
111 Systemic lupus erythematosus 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
112 T cell receptor signaling pathway 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
113 T cell receptor signaling pathway 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
114 T cell receptor signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
115 TGF-beta signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
116 Th1 and Th2 cell differentiation 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
117 Th1 and Th2 cell differentiation 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
118 Th17 cell differentiation 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
119 Th17 cell differentiation 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
120 TNF signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
121 Toll-like receptor signaling pathway 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
122 Toxoplasmosis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
123 Tuberculosis 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
124 Tuberculosis 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
125 Tuberculosis 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
126 Type I diabetes mellitus 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
127 Type II diabetes mellitus 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
128 VEGF signaling pathway 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
129 VEGF signaling pathway 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
130 Viral protein interaction with cytokine and cytokine receptor 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬
131 Wnt signaling pathway 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D00107 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
132 Wnt signaling pathway 💬
 [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 D08556 💬 Tacrolimus [34]  2 ,  6 , 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 💬
133 Yersinia infection 💬
 [1] TNF 💬 D02597 💬 Adalimumab [18] 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 151, 160, 164, 222, 226, 269, 270, 271 💬

Back to top